Did a Weight-Loss Shot Contribute to This Grandmother’s Death?
The reviews found tirzepatide, semaglutide and liraglutide all beat placebo, but long-term safety, side effects and industry influence remain unclear.
- Three recently released Cochrane reviews commissioned by the World Health Organization confirm that GLP-1 medications such as Ozempic and Wegovy lead to meaningful weight loss compared to placebos, though findings reveal critical gaps regarding long-term safety and potential industry bias.
- Originally developed for type 2 diabetes, these drugs mimic naturally occurring hormones that slow digestion and target appetite-regulating receptors; scientists have adapted them for obesity treatment as diet and exercise alone prove insufficient for many.
- Data shows participants taking semaglutide were more likely to lose at least 5% of their body weight, yet reviews noted higher rates of mild-to-moderate gastrointestinal side effects and little difference in major cardiovascular outcomes versus placebo.
- Pharmaceutical companies were deeply involved in designing, conducting, and reporting many trials; experts underscore such involvement raises potential conflicts of interest, highlighting an urgent need for more independent research.
- These findings will inform upcoming World Health Organization guidelines on obesity treatment, as authors warn expanded use must account for cost and access to avoid worsening health disparities, particularly since evidence beyond two years remains limited.
35 Articles
35 Articles
The one thing Ozempic still can’t fix
GLP-1 drugs promised to usher in a new era of treating obesity as a disease. We could leave behind the anti-fat biases of the past, which blamed obesity on moral failing or personal weakness. Instead, these drugs would allow us to approach it as a medical condition, a complex matrix of genetics and other forces which could be changed with the right dose of these powerful new medicines. Or so the thinking went. While the clinical potential of t…
Decision on publicly funded weight-loss drugs in Jersey delayed
A DECISION on whether weight-loss drugs will be publicly funded in Jersey remains on hold – seven months after it was due and more than three years after the UK first made injectable obesity medicines available on the NHS. Confirmation on whether Jersey would follow the UK in allowing doctors providing publicly funded care to […] The post Decision on publicly funded weight-loss drugs in Jersey delayed appeared first on Jersey Evening Post.
The new medications for obesity have revolutionized the treatment of excess weight and are helping thousands of people to lose weight effectively. However, as their use increases, some of its most visible effects also begin to be known.Read more]]>
Researchers Solve Mystery Behind Contradictory Weight-Loss Drug Paradox
Opposite actions on the same receptor can promote weight loss by targeting different brain circuits. Two obesity drugs can push the same brain receptor in opposite directions and still lead to weight loss. Researchers at the University of Cambridge have now traced that apparent contradiction to two separate regions of the brain. The mouse study, [...]
Coverage Details
Bias Distribution
- 52% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
